KBLB Kraig Biocraft Laboratories Inc.

24/7 Market News: Ken Le, Not Stan Lee, to Lead Prodigy Silk’s Super Fiber Deliveries to Global Brands for Kraig Labs

24/7 Market News: Ken Le, Not Stan Lee, to Lead Prodigy Silk’s Super Fiber Deliveries to Global Brands for Kraig Labs

DENVER, Sept. 09, 2025 (GLOBE NEWSWIRE) -- , a pioneer in digital media dedicated to the swift distribution of financial market news and information, analyses Kraig Biocraft Laboratories (OTCQB: KBLB), the undisputed global leader in the development and commercialization of spider silk, appointment of Kenneth Le as Managing Director of Prodigy Silk Ltd, the Company’s wholly owned recombinant spider silk production subsidiary in Southeast Asia.

The strategic promotion of Le comes at a pivotal moment. With the Company now preparing to kick off its revamped spider silk production model and focus on its first sample deliveries to three high-profile global clients, Le’s leadership is expected to catalyze the transition from production scale-up to commercial super fiber deployment.

Operational Excellence for a Next-Gen Material

Kenneth Le has been a driving force behind Kraig’s success in Southeast Asia. His leadership in daily operations and building key governmental alliances has played a direct role in establishing a solid foundation for Kraig Labs.

“Ken has been at the center of our growth story in Southeast Asia,” commented Kim Thompson, Founder and CEO of Kraig Labs. “His ability to combine operational expertise with a deep understanding of our recombinant spider silk technology makes him the ideal choice to lead Prodigy Silk.”

High-Profile Clients Await Kraig’s Spider Silk

As revealed by the Company, Kraig Labs is in ongoing commercial discussions with three global category leaders who are preparing to receive spider silk samples and initial production shipments:

  • A luxury fashion brand with an accepted quote in hand
  • A high-end performance sportswear company with budget approved for purchase
  • One of the top 5 global athletic equipment manufacturers, eyeing silk integration into next-gen products

A Commercial Turning Point: From Lab to Luxury

Kraig Labs’ double hybrid production model, on track for 2025 launch, is expected to increase silk output and has additional benefits for that places Prodigy Silk at the heart of the Company’s commercial roadmap.

As Managing Director, Le will focus on:

  • Expanding silk rearing and processing capacity
  • Ensuring production milestones align with global delivery timelines
  • Leading next-gen hybrid deployment for even greater yield

Building Toward Revenue: Inventory and Infrastructure in Place

Kraig Labs is building something extraordinary, so Ken Le is charge of making sure that the Prodigy completes a clear transition from developmental phases to volume production and delivery, a necessary step toward revenue recognition and client onboarding.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications.

For more information, please visit:

Please to read the full Kraig Labs analyst report on 247marketnews.com.

Contact for Analyst Report coverage and other investor/public relations services.

About 24/7 Market News

24/7 Market News (24/7 MN) is a leading market news platform for public companies. As a pioneer in digital media, 24/7 MN is dedicated to the swift distribution of financial market news and information. 24/7 MN takes great pride in creating innovative public relations campaigns that help clients reach the target audience.

24/7 MARKET NEWS, INC (247) Disclaimer and Disclosure

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by one or more featured companies for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247’s Full Disclaimer . Please go to for further KBLB and 247marketnews.com disclosure information.

CONTACT:

24/7 Market News

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.



EN
09/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kraig Biocraft Laboratories Inc.

 PRESS RELEASE

24/7 Market News: Kraig Labs the Bootstrapped Unicorn in the Making

24/7 Market News: Kraig Labs the Bootstrapped Unicorn in the Making DENVER, March 11, 2026 (GLOBE NEWSWIRE) -- -- In technology and biotechnology, “unicorn” status is typically reserved for private companies valued at $1 billion or more; often backed by major venture rounds, institutional syndicates, and aggressive capital deployment strategies. But what happens when a company advances a platform with billion-dollar potential without the backing of Silicon Valley mega-funding? That question is increasingly being asked about Kraig Biocraft Laboratories (OTCQB: KBLB). More than a decade ...

 PRESS RELEASE

Kraig Biocraft Laboratories Targets New Industrial and Defense Biomate...

Kraig Biocraft Laboratories Targets New Industrial and Defense Biomaterials as "Project Atlas" Hits Major Milestone ANN ARBOR, Mich., March 05, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a major milestone in "Project Atlas", the Company's next-generation bioengineering initiative aimed at creating entirely new classes of materials for industrial and defense applications. Kraig Labs first disclosed the existence of Project Atlas on January 19th, 2026, when ...

 PRESS RELEASE

24/7 Market News- “Somewhere in Michigan”: National Geographic Spotlig...

24/7 Market News- “Somewhere in Michigan”: National Geographic Spotlights Kraig Biocraft Laboratories Science Powering Recombinant Spider Silk Production March issue of National Geographic explores how engineered silkworms are spinning one of nature’s most powerful materials at scale DENVER, Feb. 24, 2026 (GLOBE NEWSWIRE) -- , a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Kraig Biocraft Laboratories (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the undisputed global leader in the development and commercialization o...

 PRESS RELEASE

Biotech Breakthroughs, Big Buyouts, Immunotherapy Momentum, and a Medi...

Biotech Breakthroughs, Big Buyouts, Immunotherapy Momentum, and a Media Megamerger DENVER, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wall Street opens to a convergence of science, scale, and strategic consolidation. From spider silk making mainstream headlines to multibillion-dollar oncology deals and accelerating immunotherapy revenues, today’s tape reflects capital flowing toward platforms with validation. Kraig Biocraft Laboratories Featured on National Geographic Cover Shares of Kraig Biocraft Laboratories (OTCQB:KBLB) could see elevated interest after the company’s recombinant spider silk ...

 PRESS RELEASE

Kraig Biocraft Laboratories’ Spider Silk Advancements Featured as the ...

Kraig Biocraft Laboratories’ Spider Silk Advancements Featured as the Cover of National Geographic's March 2026 Issue ANN ARBOR, Mich., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced that its groundbreaking work in commercializing spider silk is featured on the cover of the March 2026 issue of National Geographic magazine. National Geographic highlights Kraig Labs’ advancements in producing spider silk fibers using genetically enhanced silkworms. The ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch